News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS Michael O'Riordan March 18, 2017
News Conference News ACC 2017 iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions Caitlin E. Cox March 18, 2017
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017